Figure 2.
AUTO3 engraftment and persistence. (A) Peak AUTO3 using qPCR and AUTO3 dose or timing of pembrolizumab administration. (B) Peak AUTO3 using qPCR, and pre-LD disease burden using SPD <20 vs ≥20. Data missing for 3 patients. (C) Peak AUTO3 using qPCR and baseline CD19/22 status, in which CD19+ or CD22+ is reflected through H-score ≥150. CD19lo/– and CD22lo/– represent H-scores <150. (D) Peak AUTO3 using qPCR and disease response at month 1. (E) AUTO3 persistence using qPCR and timing of pembrolizumab. (F) AUTO3 persistence using qPCR and Tn and Tcm populations in the drug product for patients with short engraftment ≤28 days. (G) AUTO3 persistence for all patients using qPCR based on the dose. Pem, pembrolizumab. (H) AUTO3 persistence for all patients using qPCR based on the response.

AUTO3 engraftment and persistence. (A) Peak AUTO3 using qPCR and AUTO3 dose or timing of pembrolizumab administration. (B) Peak AUTO3 using qPCR, and pre-LD disease burden using SPD <20 vs ≥20. Data missing for 3 patients. (C) Peak AUTO3 using qPCR and baseline CD19/22 status, in which CD19+ or CD22+ is reflected through H-score ≥150. CD19lo/– and CD22lo/– represent H-scores <150. (D) Peak AUTO3 using qPCR and disease response at month 1. (E) AUTO3 persistence using qPCR and timing of pembrolizumab. (F) AUTO3 persistence using qPCR and Tn and Tcm populations in the drug product for patients with short engraftment ≤28 days. (G) AUTO3 persistence for all patients using qPCR based on the dose. Pem, pembrolizumab. (H) AUTO3 persistence for all patients using qPCR based on the response.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal